AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comAUG 292 min read$GMRS

GMR Solutions, Inc. Class A (GMRS) Gets a Buy from Barclays

Barclays analyst Andrew Mok maintained a Buy rating on GMR Solutions, Inc. Class A (GMRS) with a $16.00 price target. Goldman Sachs also issued a Buy rating, while Morgan Stanley assigned a Hold. GMRS reported Q2 revenue of $1.49B and a GAAP net loss of $28.28M.

Original reporting
theglobeandmail.com
Published Aug 29, 2026, 8:37 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 30, 2026, 4:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
GMR Solutions, Inc. Class A (GMRS) Gets a Buy from Barclays — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$GMRSNeutralMed
01

Why it matters

Analyst upgrades could offset earnings disappointment, creating a short‑term trade opportunity.

02

Market read

Earnings and rating update provide fresh data for traders in the healthcare small‑cap space.

03

What to watch

No guidance provided; market may price in future earnings risk.

Relevance 6/10Novelty 7/10Timing: pre-market

Background

GMR Solutions reported Q2 2026 results and received mixed analyst ratings.

Company-level read

Ticker impact

$GMRSNeutralMedium confidence
Context

Barclays maintains a Buy rating and sets a $16 price target; earnings release shows $1.49B revenue and a $28.28M loss.

Expected impact

Possible modest price rise on the buy rating, but downside risk from loss.

Evidence & confidence

Buy rating adds support, but loss signals earnings weakness.

Market effects

Sector

Healthcare sector may see slight lift from analyst coverage of peers.

Regional

US small‑cap healthcare stocks could see modest interest.

Global

Limited to US investors.

Counterpoint

What could challenge this read

Loss may outweigh rating upgrade; consider short position.

Key entities

  • Company
    GMR Solutions, Inc. Class A

    Healthcare services provider listed on NYSE.

  • Analyst
    Barclays

    Maintained Buy rating with $16 target.

Read at source← All news

Related articles

AUG 12
$GMRSMed

GMR Solutions Inc. (GMRS): Results of Operations and Financial Condition

GMR Solutions Inc. (GMRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ GMR Solutions Inc. Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Reaffirms Full Year 2026 Guidance LEWISVILLE, Texas (August 12, 2026) — GMR Solutions Inc. (“GMR” or the “Company”) (NYSE: GMRS), the nation’s largest provider of em

SEC EDGAR 8-K6 min
JUN 11
$PBLSMed

Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch

Biotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.

rttnews.com7 min
JUN 2
$GMRSMedAI 9/10

Full Transcript: GMR Solutions Q1 2026 Earnings Call - GMR Solutions (NYSE:GMRS)

GMR Solutions (NYSE:GMRS) reported Q1 2026 revenue of $1.46 billion (+6.6% YoY) and adjusted EBITDA of $305 million (+9.7%). The company said its recent IPO leaves net leverage around 3.5x. It cited a 47% rise in 911 nurse navigation calls and nearly $47 million in incremental annualized revenue from new agreements. 2026 guidance targets $5.89–$6.18 billion revenue and high single-digit adjusted EBITDA growth.

benzinga.com12 min